Tumor Board Articles

Immunotherapy for HCC has transformed treatment for advanced liver cancer, with landmark trials like IMbrave150, Himalaya, and CheckMate-9DW redefining first-line options. Learn about these trials and their implications for survival benefits, combination strategies, and the role of tumor etiology.

Portal Vein Thrombosis (PVT) can complicate liver transplant eligibility and surgical planning. Learn how transplant teams assess and manage PVT in liver transplant candidates, including surgical, interventional, and anticoagulative strategies.

Post-transplant HCC recurrence poses a considerable challenge and requires comprehensive surveillance and interventional management. Learn about key approaches to managing HCC recurrence and other post-transplant complications such as biliary stricture and organ rejection.